Catalyst Pharmaceuticals Inc

CPRX's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

CPRX Growth rates comparisons

Looking into Catalyst Pharmaceuticals Inc growth rates, revenue grew by 15.31 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 1107

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.1 %

Catalyst Pharmaceuticals Inc 's net income grew by 20.28 % in third quarter of 2025 year on year, above company average,

• More on CPRX's Growth

CPRX's Valuation comparisons

Catalyst Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Catalyst Pharmaceuticals Inc PEG ratio is at 0.34 Company is currently trading with Price to Cash flow multiple of 12.08 in trailing twelve-month period.

Company

14.13

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 5.17.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 6.17.

• More on CPRX's Valuation

Total Debt (Millions $)	-
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	5,454,679
Net Income/Employee (TTM) $	2,052,491
Receivable Turnover (TTM)	7.48
Tangible Book Value (Per Share $)	6.23

CPRX's Valuation comparisons

Company

14.13

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 5.17.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 6.17.

Catalyst Pharmaceuticals Inc Price to Book Ratio is at 3.25 lower than Industry Avg. of 111.43. and higher than S&P 500 Avg. of 0.02

• More on CPRX's Valuation

• Market Capitalization (Millions $)	2,990
• Shares Outstanding (Millions)	127
• Employees	106
• Revenues (TTM) (Millions $)	578
• Net Income (TTM) (Millions $)	218
• Cash Flow (TTM) (Millions $)	248
• Capital Exp. (TTM) (Millions $)	-
• Total Debt (Millions $)	-
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	5,454,679
• Net Income/Employee(TTM) $	2,052,491
• Receivable Turnover Ratio (TTM)	7.48
• Tangible Book Value (Per Share $)	6.23

• Market Capitalization (Millions $)	2,990
• Shares Outstanding (Millions)	127
• Employees	106
• Revenues (TTM) (Millions $)	578
• Net Income (TTM) (Millions $)	218
• Cash Flow (TTM) (Millions $)	248
• Capital Exp. (TTM) (Millions $)	-

CPRX's Profitability Comparisons

Catalyst Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in third quarter of 2025 to 44.66 % from 45.24 % in II. Quarter.

Catalyst Pharmaceuticals Inc net profit margin of 35.57 % is currently ranking no. 23 in Major Pharmaceutical Preparations industry, ranking no. 36 in Healthcare sector and number 322 in S&P 500.

Profitability by Segment
Total	35.57 %

	*Ratio*
• Capital Ratio (MRQ)	6.62
• Total Debt to Equity (MRQ)	-
• Tangible Leverage Ratio (MRQ)	0.17
• Asset Turnover Ratio (TTM)	0.61
• Inventory Turnover Ratio (TTM)	3.85

CPRX's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.